Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Intranasal RSV Vaccine MV-012-968 in Seropositive Children
NCT04444284Phase 1Completed
- Sponsor
- Meissa Vaccines
- Start
- Jun 2020
- Primary completion
- May 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of MV-012-968 in respiratory syncytial virus infection (RSV) (5 arms), sponsored by Meissa Vaccines. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 2 more. Started Jun 2020; status: completed.
02
Drugs
MV-012-968
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04444284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04444284.